Dr. Anna Halpern
Claim this profileUniversity of Washington
Studies Acute Myelogenous Leukemia
Studies Myelodysplastic Syndrome
5 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Anna Halpern is currently running
Decitabine + JAK Inhibitors
for Advanced Myeloproliferative Disorders
This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ruxolitinib, fedratinib, and pacritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a donor hematopoietic stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells. Decitabine, with ruxolitinib, fedratinib, or pacritinib may work better than multi-agent chemotherapy or no pre-transplant therapy, in treating patients with accelerated/blast phase myeloproliferative neoplasms.
Recruiting1 award Phase 211 criteria
Red Blood Cell Transfusions
for Leukemia
This clinical trial evaluates the effects of hemoglobin threshold-specific packed red blood cell (PRBC) transfusions on quality of life and functional outcomes in patients who have undergone chemotherapy or an allogeneic hematopoietic stem cell transplant for a high-grade myeloid neoplasm, acute myeloid leukemia, or B acute lymphoblastic lymphoma/leukemia. Some types of chemotherapy and stem cell transplants can induce low platelet counts and/or anemia that requires PRBC transfusions. Given critical shortages in blood supply, and risks associated with transfusion of PRBC, there has been much investigation into the "minimum" hemoglobin level that effectively balances safety and toxicity in patients. This clinical trial evaluates the effects of giving PRBC transfusions based on a more restrictive hemoglobin threshold (\> 7 gm/dL) compared to a more liberal hemoglobin threshold (\> 9 gm/dL) on quality of life and functional outcomes. A more restrictive threshold may be just as effective at maintaining patient quality of life and function while decreasing side effects from blood transfusions and helping to conserve blood supply resources.
Recruiting1 award N/A4 criteria
More about Anna Halpern
Clinical Trial Related5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Anna Halpern has experience with
- Packed Red Blood Cell Transfusion
- Decitabine
- Fedratinib
- Ruxolitinib
- KPT-8602
- DISC-0974
Breakdown of trials Anna Halpern has run
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Myeloproliferative Disorder
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anna Halpern specialize in?
Anna Halpern focuses on Acute Myelogenous Leukemia and Myelodysplastic Syndrome. In particular, much of their work with Acute Myelogenous Leukemia has involved treating patients, or patients who are undergoing treatment.
Is Anna Halpern currently recruiting for clinical trials?
Yes, Anna Halpern is currently recruiting for 3 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Anna Halpern has studied deeply?
Yes, Anna Halpern has studied treatments such as Packed Red Blood Cell Transfusion, Decitabine, Fedratinib.
What is the best way to schedule an appointment with Anna Halpern?
Apply for one of the trials that Anna Halpern is conducting.
What is the office address of Anna Halpern?
The office of Anna Halpern is located at: University of Washington, Seattle, Washington 98109 United States. This is the address for their practice at the University of Washington.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.